Expanding the opportunities for modulating kinase targets with allosteric approaches

Current Topics in Medicinal Chemistry

Volumn 17, Issue 1, 2017, Pages 59-70

  Möbitz, Henrik ^a   Jahnke, Wolfgang ^a   Cowan Jacob, Sandra W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Activator; Allosteric; Binding mode; Inhibitor; Kinase; Structure Based Drug Discovery; Target Space

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENOSINE TRIPHOSPHATE; ALLOSTERIC KINASE INHIBITOR; ASCIMINIB; B RAF KINASE; CYCLIN DEPENDENT KINASE 2; DASATINIB; ENCORAFENIB; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GNF2 PROTEIN; GUANOSINE TRIPHOSPHATASE; IMATINIB; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; NILOTINIB; P21 ACTIVATED KINASE 1; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ALLOSTERISM; BINDING ASSAY; BINDING SITE; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG DESIGN; ENZYME INHIBITION; GENE MUTATION; HUMAN; IC50; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; VALIDATION PROCESS; METABOLISM;

ALLOSTERIC REGULATION; BINDING SITES; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 85011750087     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160719165314     Document Type: Review

References (71)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S., The protein kinase complement of the human genome. Science, 2002, 298 (5600), 1912-34
2. Knighton, D. R.; Zheng, J. H.; Ten Eyck, L. F.; Ashford, V. A.; Xuong, N. H.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science, 1991, 253 (5018), 407-14.
3. Fedorov, O.; Muller, S.; Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Boil., 2010, 6 (3), 166-169.
4. Fabbro, D., 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol. Pharmacol., 2015, 87 (5), 766-75.
5. Rauch, J.; Volinsky, N.; Romano, D.; Kolch, W. The secret life of kinases: functions beyond catalysis. Cell communication and signaling: CCS 2011, 9 (1), 23.
6. Cowan-Jacob, S. W.; Jahnke, W.; Knapp, S. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med. Chem., 2014, 6 (5), 541-61.
7. Posas, F.; Saito, H. Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: scaffold role of Pbs2p MAPKK. Science, 1997, 276 (5319), 1702-5.
8. Iwatani, M.; Iwata, H.; Okabe, A.; Skene, R. J.; Tomita, N.; Hayashi, Y.; Aramaki, Y.; Hosfield, D. J.; Hori, A.; Baba, A.; Miki, H., Discovery and characterization of novel allosteric FAK inhibitors. Euro. J. Med. Chem., 2013, 61, 49-60
9. Viaud, J.; Peterson, J. R. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer Ther., 2009, 8 (9), 2559-65
10. Karpov, A. S.; Amiri, P.; Bellamacina, C.; Bellance, M. H.; Breitenstein, W.; Daniel, D.; Denay, R.; Fabbro, D.; Fernandez, C.; Galuba, I.; Guerro-Lagasse, S.; Gutmann, S.; Hinh, L.; Jahnke, W.; Klopp, J.; Lai, A.; Lindvall, M. K.; Ma, S.; Mobitz, H.; Pecchi, S.; Rummel, G.; Shoemaker, K.; Trappe, J.; Voliva, C.; Cowan-Jacob, S. W.; Marzinzik, A. L. Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. ACS Med. Chem. Lett., 2015, 6 (7), 776-81
11. Vanderpool, D.; Johnson, T. O.; Ping, C.; Bergqvist, S.; Alton, G.; Phonephaly, S.; Rui, E.; Luo, C.; Deng, Y. L.; Grant, S.; Quenzer, T.; Margosiak, S.; Register, J.; Brown, E.; Ermolieff, J. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry, 2009, 48 (41), 9823-30.
12. Jubb, H.; Higueruelo, A. P.; Winter, A.; Blundell, T. L. Structural biology and drug discovery for protein-protein interactions. Trends in Pharmacol. Sci., 2012, 33 (5), 241-8.
13. Jahnke, W.; Grotzfeld, R. M.; Pelle, X.; Strauss, A.; Fendrich, G.; Cowan-Jacob, S. W.; Cotesta, S.; Fabbro, D.; Furet, P.; Mestan, J.; Marzinzik, A. L. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J. Am. Chem. Soc., 2010, 132 (20), 7043-8.
14. Bono, F.; De Smet, F.; Herbert, C.; De Bock, K.; Georgiadou, M.; Fons, P.; Tjwa, M.; Alcouffe, C.; Ny, A.; Bianciotto, M.; Jonckx, B.; Murakami, M.; Lanahan, A. A.; Michielsen, C.; Sibrac, D.; Dol-Gleizes, F.; Mazzone, M.; Zacchigna, S.; Herault, J. P.; Fischer, C.; Rigon, P.; Ruiz de Almodovar, C.; Claes, F.; Blanc, I.; Poesen, K.; Zhang, J.; Segura, I.; Gueguen, G.; Bordes, M. F.; Lambrechts, D.; Broussy, R.; van de Wouwer, M.; Michaux, C.; Shimada, T.; Jean, I.; Blacher, S.; Noel, A.; Motte, P.; Rom, E.; Rakic, J. M.; Katsuma, S.; Schaeffer, P.; Yayon, A.; Van Schepdael, A.; Schwalbe, H.; Gervasio, F. L.; Carmeliet, G.; Rozensky, J.; Dewerchin, M.; Simons, M.; Christopoulos, A.; Herbert, J. M.; Carmeliet, P. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer cell, 2013, 23 (4), 477-88
15. Hall, J.; Aulabaugh, A.; Rajamohan, F.; Liu, S.; Kaila, N.; Wan, Z. K.; Ryan, M.; Magyar, R.; Qiu, X. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase. J. Biol. Chem., 2012, 287 (10), 7717-27.
16. Mobitz, H. The ABC of protein kinase conformations. Biochimica et biophysica acta, 2015, 1854 (10 Pt B), 1555-66.
17. Wylie, A.; Schoepfer, J.; Berellini, G.; Cai, H. B.; Caravatti, G.; Cotesta, S.; Dodd, S.; Donovan, J.; Erb, B.; Furet, P.; Gangal, G.; Grotzfeld, R.; Hassan, Q.; Hood, T.; Iyer, V.; Jacob, S.; Jahnke, W.; Lombardo, F.; Loo, A.; Manley, P. W.; Marzinzik, A.; Palmer, M.; Pelle, X.; Salem, B.; Sharma, S.; Thohan, S.; Zhu, S.; Keen, N.; Petruzzelli, L.; Vanasse, K. G.; Sellers, W. R. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Re sistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia. Blood, 2014, 124 (21).
18. Sadowsky, J. D.; Burlingame, M. A.; Wolan, D. W.; McClendon, C. L.; Jacobson, M. P.; Wells, J. A. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl. Acad. Sci. U.S.A., 2011, 108 (15), 6056-61.
19. Tzarum, N.; Komornik, N.; Ben Chetrit, D.; Engelberg, D.; Livnah, O. DEF pocket in p38alpha facilitates substrate selectivity and mediates autophosphorylation. J. Biol. Chem., 2013, 288 (27), 19537-47.
20. Pymol, The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.
21. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2 (7), 358-64.
22. Wu, W. I.; Voegtli, W. C.; Sturgis, H. L.; Dizon, F. P.; Vigers, G. P.; Brandhuber, B. J. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PloS one, 2010, 5 (9), e12913
23. Xie, T.; Peng, W.; Liu, Y.; Yan, C.; Maki, J.; Degterev, A.; Yuan, J.; Shi, Y. Structural basis of RIP1 inhibition by necrostatins. Structure, 2013, 21 (3), 493-9.
24. Alexander, L. T.; Mobitz, H.; Drueckes, P.; Savitsky, P.; Fedorov, O.; Elkins, J. M.; Deane, C. M.; Cowan-Jacob, S. W.; Knapp, S. Type II Inhibitors Targeting CDK2. ACS Chem. Biol., 2015, 10 (9), 2116-25.
25. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N. S. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol., 2014, 9 (6), 1230-41.
26. Yang, J.; Cron, P.; Thompson, V.; Good, V. M.; Hess, D.; Hemmings, B. A.; Barford, D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell, 2002, 9 (6), 1227-40.
27. Converso, A.; Hartingh, T.; Garbaccio, R. M.; Tasber, E.; Rickert, K.; Fraley, M. E.; Yan, Y.; Kreatsoulas, C.; Stirdivant, S.; Drakas, B.; Walsh, E. S.; Hamilton, K.; Buser, C. A.; Mao, X.; Abrams, M. T.; Beck, S. C.; Tao, W.; Lobell, R.; Sepp-Lorenzino, L.; Zugay-Murphy, J.; Sardana, V.; Munshi, S. K.; Jezequel-Sur, S. M.; Zuck, P. D.; Hartman, G. D. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19 (4), 1240-4.
28. Comess, K. M.; Sun, C.; Abad-Zapatero, C.; Goedken, E. R.; Gum, R. J.; Borhani, D. W.; Argiriadi, M.; Groebe, D. R.; Jia, Y.; Clampit, J. E.; Haasch, D. L.; Smith, H. T.; Wang, S.; Song, D.; Coen, M. L.; Cloutier, T. E.; Tang, H.; Cheng, X.; Quinn, C.; Liu, B.; Xin, Z.; Liu, G.; Fry, E. H.; Stoll, V.; Ng, T. I.; Banach, D.; Marcotte, D.; Burns, D. J.; Calderwood, D. J.; Hajduk, P. J. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem. Biol., 2011, 6 (3), 234-44.
29. Yang, J.; Campobasso, N.; Biju, M. P.; Fisher, K.; Pan, X. Q.; Cottom, J.; Galbraith, S.; Ho, T.; Zhang, H.; Hong, X.; Ward, P.; Hofmann, G.; Siegfried, B.; Zappacosta, F.; Washio, Y.; Cao, P.; Qu, J.; Bertrand, S.; Wang, D. Y.; Head, M. S.; Li, H.; Moores, S.; Lai, Z.; Johanson, K.; Burton, G.; Erickson-Miller, C.; Simpson, G.; Tummino, P.; Copeland, R. A.; Oliff, A. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Boil., 2011, 18 (2), 177-86.
30. Hindie, V.; Stroba, A.; Zhang, H.; Lopez-Garcia, L. A.; Idrissova, L.; Zeuzem, S.; Hirschberg, D.; Schaeffer, F.; Jorgensen, T. J.; Engel, M.; Alzari, P. M.; Biondi, R. M. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Boil., 2009, 5 (10), 758-64.
31. Goransson, O.; McBride, A.; Hawley, S. A.; Ross, F. A.; Shpiro, N.; Foretz, M.; Viollet, B.; Hardie, D. G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMPactivated protein kinase. J. Chem. Boil., 2007, 282 (45), 32549-60.
32. Xiao, B.; Sanders, M. J.; Carmena, D.; Bright, N. J.; Haire, L. F.; Underwood, E.; Patel, B. R.; Heath, R. B.; Walker, P. A.; Hallen, S.; Giordanetto, F.; Martin, S. R.; Carling, D.; Gamblin, S. J. Structural basis of AMPK regulation by small molecule activators. Nat. Commun., 2013, 4, 3017.
33. Calabrese, M. F.; Rajamohan, F.; Harris, M. S.; Caspers, N. L.; Magyar, R.; Withka, J. M.; Wang, H.; Borzilleri, K. A.; Sahasrabudhe, P. V.; Hoth, L. R.; Geoghegan, K. F.; Han, S.; Brown, J.; Subashi, T. A.; Reyes, A. R.; Frisbie, R. K.; Ward, J.; Miller, R. A.; Landro, J. A.; Londregan, A. T.; Carpino, P. A.; Cabral, S.; Smith, A. C.; Conn, E. L.; Cameron, K. O.; Qiu, X.; Kurumbail, R. G. Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms. Structure, 2014, 22 (8), 1161-72.
34. Raaf, J.; Guerra, B.; Neundorf, I.; Bopp, B.; Issinger, O. G.; Jose, J.; Pietsch, M.; Niefind, K. First structure of protein kinase CK2 catalytic subunit with an effective CK2beta-competitive ligand. ACS Chem. Boil., 2013, 8 (5), 901-7.
35. Ashwell, M. A.; Lapierre, J. M.; Brassard, C.; Bresciano, K.; Bull, C.; Cornell-Kennon, S.; Eathiraj, S.; France, D. S.; Hall, T.; Hill, J.; Kelleher, E.; Khanapurkar, S.; Kizer, D.; Koerner, S.; Link, J.; Liu, Y.; Makhija, S.; Moussa, M.; Namdev, N.; Nguyen, K.; Nicewonger, R.; Palma, R.; Szwaya, J.; Tandon, M.; Uppalapati, U.; Vensel, D.; Volak, L. P.; Volckova, E.; Westlund, N.; Wu, H.; Yang, R. Y.; Chan, T. C. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J. Med. Chem., 2012, 55 (11), 5291-310.
36. Heinrich, T.; Gradler, U.; Bottcher, H.; Blaukat, A.; Shutes, A. Allosteric IGF-1R Inhibitors. ACS Med. Chem. Lett., 2010, 1 (5), 199-203.
37. Salah, E.; Ugochukwu, E.; Barr, A. J.; von Delft, F.; Knapp, S.; Elkins, J. M., Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J. Med. Chem., 2011, 54 (7), 2359-67.
38. Han, S.; Czerwinski, R. M.; Caspers, N. L.; Limburg, D. C.; Ding, W.; Wang, H.; Ohren, J. F.; Rajamohan, F.; McLellan, T. J.; Unwalla, R.; Choi, C.; Parikh, M. D.; Seth, N.; Edmonds, J.; Phillips, C.; Shakya, S.; Li, X.; Spaulding, V.; Hughes, S.; Cook, A.; Robinson, C.; Mathias, J. P.; Navratilova, I.; Medley, Q. G.; Anderson, D. R.; Kurumbail, R. G.; Aulabaugh, A., Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors. Biochem. J., 2014, 460 (2), 211-22.
39. Smith, C. K.; Windsor, W. T., Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry. Biochem., 2007, 46 (5), 1358-67.
40. Karni, R.; Mizrachi, S.; Reiss-Sklan, E.; Gazit, A.; Livnah, O.; Levitzki, A., The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett. 2003, 537 (1-3), 47-52.
41. Eathiraj, S.; Palma, R.; Hirschi, M.; Volckova, E.; Nakuci, E.; Castro, J.; Chen, C. R.; Chan, T. C.; France, D. S.; Ashwell, M. A. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J. Biol. Chem., 2011, 286 (23), 20677-87.
42. Blat, Y. Non-competitive inhibition by active site binders. Chem. Biol. Drug Design, 2010, 75 (6), 535-40.
43. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293 (5531), 876-80.
44. Cowan-Jacob, S. W.; Guez, V.; Fendrich, G.; Griffin, J. D.; Fabbro, D.; Furet, P.; Liebetanz, J.; Mestan, J.; Manley, P. W. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem., 2004, 4 (3), 285-99.
45. Nagar, B.; Hantschel, O.; Young, M. A.; Scheffzek, K.; Veach, D.; Bornmann, W.; Clarkson, B.; Superti-Furga, G.; Kuriyan, J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell, 2003, 112 (6), 859-71.
46. Hantschel, O.; Nagar, B.; Guettler, S.; Kretzschmar, J.; Dorey, K.; Kuriyan, J.; Superti-Furga, G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell, 2003, 112 (6), 845-57.
47. Adrian, F. J.; Ding, Q.; Sim, T.; Velentza, A.; Sloan, C.; Liu, Y.; Zhang, G.; Hur, W.; Ding, S.; Manley, P.; Mestan, J.; Fabbro, D.; Gray, N. S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol., 2006, 2 (2), 95-102.
48. Zhang, J.; Adrian, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G. R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature, 2010, 463 (7280), 501-6.
49. Bhang, H. E.; Ruddy, D. A.; Krishnamurthy Radhakrishna, V.; Caushi, J. X.; Zhao, R.; Hims, M. M.; Singh, A. P.; Kao, I.; Rakiec, D.; Shaw, P.; Balak, M.; Raza, A.; Ackley, E.; Keen, N.; Schlabach, M. R.; Palmer, M.; Leary, R. J.; Chiang, D. Y.; Sellers, W. R.; Michor, F.; Cooke, V. G.; Korn, J. M.; Stegmeier, F. Studying clonal dynamics in response to cancer therapy using highcomplexity barcoding. Nat. Med., 2015, 21 (5), 440-8.
50. Rudolph, J.; Crawford, J. J.; Hoeflich, K. P.; Wang, W. Inhibitors of p21-activated kinases (PAKs). J. Med. Chem., 2015, 58 (1), 111-29.
51. Eswaran, J.; Soundararajan, M.; Kumar, R.; Knapp, S. UnPAKing the class differences among p21-activated kinases. Trends in Biochem. Sci., 2008, 33 (8), 394-403.
52. Baker, N. M.; Yee Chow, H.; Chernoff, J.; Der, C. J. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin. Cancer Res., 2014, 20 (18), 4740-6.
53. Radu, M.; Semenova, G.; Kosoff, R.; Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer, 2014, 14 (1), 13-25.
54. Murray, B. W.; Guo, C.; Piraino, J.; Westwick, J. K.; Zhang, C.; Lamerdin, J.; Dagostino, E.; Knighton, D.; Loi, C. M.; Zager, M.; Kraynov, E.; Popoff, I.; Christensen, J. G.; Martinez, R.; Kephart, S. E.; Marakovits, J.; Karlicek, S.; Bergqvist, S.; Smeal, T. Smallmolecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. U.S.A., 2010, 107 (20), 9446-51.
55. Licciulli, S.; Maksimoska, J.; Zhou, C.; Troutman, S.; Kota, S.; Liu, Q.; Duron, S.; Campbell, D.; Chernoff, J.; Field, J.; Marmorstein, R.; Kissil, J. L. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J. Biol. Chem., 2013, 288 (40), 29105-14.
56. Staben, S. T.; Feng, J. A.; Lyle, K.; Belvin, M.; Boggs, J.; Burch, J. D.; Chua, C. C.; Cui, H.; DiPasquale, A. G.; Friedman, L. S.; Heise, C.; Koeppen, H.; Kotey, A.; Mintzer, R.; Oh, A.; Roberts, D. A.; Rouge, L.; Rudolph, J.; Tam, C.; Wang, W.; Xiao, Y.; Young, A.; Zhang, Y.; Hoeflich, K. P. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. J. Med. Chem., 2014, 57 (3), 1033-45.
57. Deacon, S. W.; Beeser, A.; Fukui, J. A.; Rennefahrt, U. E.; Myers, C.; Chernoff, J.; Peterson, J. R. An isoform-selective, smallmolecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol., 2008, 15 (4), 322-31.
58. Papa, F. R.; Zhang, C.; Shokat, K.; Walter, P. Bypassing a kinase activity with an ATP-competitive drug. Science, 2003, 302 (5650), 1533-7.
59. Tokarski, J. S.; Zupa-Fernandez, A.; Tredup, J. A.; Pike, K.; Chang, C.; Xie, D.; Cheng, L.; Pedicord, D.; Muckelbauer, J.; Johnson, S. R.; Wu, S.; Edavettal, S. C.; Hong, Y.; Witmer, M. R.; Elkin, L. L.; Blat, Y.; Pitts, W. J.; Weinstein, D. S.; Burke, J. R. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J. Biol. Chem., 2015, 290 (17), 11061-74.
60. Hammaren, H. M.; Ungureanu, D.; Grisouard, J.; Skoda, R. C.; Hubbard, S. R.; Silvennoinen, O. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc. Natl. Acad. Sci. U.S.A., 2015, 112 (15), 4642-7.
61. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467 (7315), 596-9.
62. Peng, S. B.; Henry, J. R.; Kaufman, M. D.; Lu, W. P.; Smith, B. D.; Vogeti, S.; Rutkoski, T. J.; Wise, S.; Chun, L.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Zhang, X.; Yadav, V.; Chen, S. H.; Gong, X.; Ma, X.; Webster, Y.; Buchanan, S.; Mochalkin, I.; Huber, L.; Kays, L.; Donoho, G. P.; Walgren, J.; McCann, D.; Patel, P.; Conti, I.; Plowman, G. D.; Starling, J. J.; Flynn, D. L. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer cell, 2015, 28 (3), 384-98.
63. Yao, Z.; Torres, N. M.; Tao, A.; Gao, Y.; Luo, L.; Li, Q.; de Stanchina, E.; Abdel-Wahab, O.; Solit, D. B.; Poulikakos, P. I.; Rosen, N. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell, 2015, 28 (3), 370-83.
64. Haling, J. R.; Sudhamsu, J.; Yen, I.; Sideris, S.; Sandoval, W.; Phung, W.; Bravo, B. J.; Giannetti, A. M.; Peck, A.; Masselot, A.; Morales, T.; Smith, D.; Brandhuber, B. J.; Hymowitz, S. G.; Malek, S. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer cell, 2014, 26 (3), 402-13.
65. Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; Salton, M.; Dahlman, K. B.; Tadi, M.; Wargo, J. A.; Flaherty, K. T.; Kelley, M. C.; Misteli, T.; Chapman, P. B.; Sosman, J. A.; Graeber, T. G.; Ribas, A.; Lo, R. S.; Rosen, N.; Solit, D. B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480 (7377), 387-90.
66. Thevakumaran, N.; Lavoie, H.; Critton, D. A.; Tebben, A.; Marinier, A.; Sicheri, F.; Therrien, M. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat. Struct. Mol. Biol., 2015, 22 (1), 37-43.
67. Betzi, S.; Alam, R.; Martin, M.; Lubbers, D. J.; Han, H.; Jakkaraj, S. R.; Georg, G. I.; Schonbrunn, E. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol., 2011, 6 (5), 492-501.
68. Chrencik, J. E.; Patny, A.; Leung, I. K.; Korniski, B.; Emmons, T. L.; Hall, T.; Weinberg, R. A.; Gormley, J. A.; Williams, J. M.; Day, J. E.; Hirsch, J. L.; Kiefer, J. R.; Leone, J. W.; Fischer, H. D.; Sommers, C. D.; Huang, H. C.; Jacobsen, E. J.; Tenbrink, R. E.; Tomasselli, A. G.; Benson, T. E. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol., 2010, 400 (3), 413-33.
69. Goodwin, N. C.; Cianchetta, G.; Burgoon, H. A.; Healy, J.; Mabon, R.; Strobel, E. D.; Allen, J.; Wang, S.; Hamman, B. D.; Rawlins, D. B. Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. ACS Med. Chem. Lett., 2015, 6 (1), 53-7.
70. Fischmann, T. O.; Smith, C. K.; Mayhood, T. W.; Myers, J. E.; Reichert, P.; Mannarino, A.; Carr, D.; Zhu, H.; Wong, J.; Yang, R. S.; Le, H. V.; Madison, V. S. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry, 2009, 48 (12), 2661-74.
71. Over, B.; Wetzel, S.; Grutter, C.; Nakai, Y.; Renner, S.; Rauh, D.; Waldmann, H. Natural-product-derived fragments for fragmentbased ligand discovery. Nat. Chem., 2013, 5 (1), 21-8.